SH3BP1

Across TCGA pan-cancer cohorts, SH3BP1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SH3BP1 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SH3BP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SH3BP1 expression acts as an unfavorable survival marker.

LUAD, ACC, and GBM are the cancer types where SH3BP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.147	0.709	<.001	24	view →
ACC	DFS	Median	All	0.195	0.748	.003	15	view →
GBM	OS	Median	All	0.109	0.415	.032	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SH3BP1–LUAD (OS)

Open the LUAD breakdown →